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ABSTRACT 
BACKGROUND: Curcumin, the principal curcuminoid derived from the spice turmeric, influences several 
biological mechanisms associated with major depression, namely those associated with monoaminergic 
activity, immune-inflammatory and oxidative & nitrosative stress pathways, hypothalamus-pituitary-adrenal 
(HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the 
treatment of depressive symptoms in individuals with major depressive disorder.  
METHODS: In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive 
disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was 
the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included 
IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI). 
RESULTS: From baseline to week 4, both curcumin and placebo were associated with improvements in 
IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly 
more effective than placebo in improving several mood-related symptoms, demonstrated by a significant 
group x time interaction for IDS-SR30 total score (F1,53 = 4.22, p = .045) and IDS-SR30 mood score (F1,53 = 
6.51, p = .014), and a non-significant trend for STAI trait score (F1,48 = 2.86, p = .097). Greater efficacy from 
curcumin treatment was identified in a subgroup of individuals with atypical depression. 
CONCLUSIONS: Partial support is provided for the antidepressant effects of curcumin in people with major 
depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.  
LIMITATIONS: Investigations with larger sample sizes, over extended treatment periods, and with varying 
curcumin dosages are required. 
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INTRODUCTION 
Disturbances in monoaminergic neurotransmission, particularly around serotonin availability, 
were originally posited as the primary cause of major depression (Cowen, 2008). However, studies 
now confirm that major depression is associated with a large array of biological disturbances. These 
include dysregulation in the hypothalamus-pituitary-adrenal (HPA) axis, activation of immune-
inflammatory pathways, increased oxidative and nitrosative stress, neuroprogression, and 
mitochondrial dysfunction (Leonard and Maes, 2012, Maes et al., 2011). Consequently, this has 
sparked interest in compounds that target these pathways. Examples include anti-inflammatory 
treatments influencing immuno-inflammation such as cyclooxygensase-2 (COX-2) inhibitors, 
aspirin, minocycline and polyunsaturated fatty acids (Berk et al., 2013a, Fond et al., 2014, Muller, 
2013) and antioxidant therapies to increase antioxidant defences and lower free radical damage such 
as n-acetyl cysteine, Ebselen, vitamin E and coenzyme-Q10 (Berk et al., 2013b, Scapagnini et al., 
2012). Interestingly, despite pharmaceutical antidepressants originally being heralded as targeting 
monoaminergic actions, there is also evidence that they can modulate immuno-inflammation, 
reduce oxidative stress, enhance neurotrophic factors and influence HPA activity (Abdel-Wahab 
and Salama, 2011, Andrade and Rao, 2010, Hannestad et al., 2011, Kocki et al., 2012, Schule, 
2007). 
Curcumin is the most active compound of the Indian spice turmeric and comprises 2-8% of most 
turmeric preparations (Sharma et al., 2005). Curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione] is a low molecular weight polyphenol, first chemically characterised in 1910 
by Milobedzka et al. (1910) and influences all of the aforementioned biological mechanisms 
(Aggarwal and Harikumar, 2009, Lopresti et al., 2012). More specifically, curcumin is a potent 
antioxidant that can lower markers of oxidative stress (Naik et al., 2011, Rai et al., 2010), modulate 
immuno-inflammation by acting as a COX-2 inhibitor (Lee et al., 2011, Plummer et al., 1999) and 
lower pro-inflammatory cytokines (Basnet and Skalko-Basnet, 2011, Belcaro et al., 2010), provide 
significant neuroprotection (Huang et al., 2011, Xu et al., 2007), modulate HPA activity (Huang et 
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al., 2011, Li et al., 2009) and influence monoamine transmission through its effect on serotonergic 
and dopaminergic activity (Bhutani et al., 2009, Kulkarni et al., 2008, Xia et al., 2007). In animal 
studies, antidepressant effects of curcumin have been attributed to its serotonergic, dopaminergic, 
neuroprotective and HPA-modulating effects (Huang et al., 2011, Kulkarni et al., 2008, Xu et al., 
2006). Two clinical trials have also now been completed investigating the antidepressant effects of 
curcumin in people with major depression. In the first study, curcumin as an add-on to 
antidepressant therapy did not enhance treatment outcome (Bergman et al., 2013), whereas in the 
second trial curcumin demonstrated similar antidepressant efficacy to fluoxetine (Sanmukhani et al., 
2014). However, the latter study lacked a placebo-control and volunteers were not blinded. 
The purpose of this study was to expand investigation into the antidepressant effects of curcumin 
supplementation in people with major depressive disorder. It was hypothesised that treatment with 
curcumin would lead to greater antidepressant benefits than a placebo, reflected by reductions in the 
administered depression and other mood-related self-report questionnaires. Curcumin was also 
hypothesised to have greater benefits for participants with atypical depression as it is associated 
with dysregulated immune-inflammatory pathways (Hickman et al., 2013, Lamers et al., 2013). 
MATERIALS AND METHODS 
Study design 
This study was an 8-week, randomised, double-blind, placebo-controlled clinical trial (Figure 1). 
The trial protocol was approved by the Human Research Ethics Committee at Murdoch University, 
Western Australia. The trial was registered with the Australian New Zealand Clinical Trials 
Registry (no. 12612001260819) and participants were recruited between February and November 
2013, across the Perth, Western Australia metropolitan area. Recruitment occurred through 
advertisements and promotions in community newspapers and a health magazine, and after 
interviews with local radio media outlets.  
Participants were randomly and equally allocated into two groups (placebo and curcumin) using 
a randomisation calculator (http://www.randomization.com). Both curcumin and placebo capsules 
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were packed in identical containers labelled by participant code numbers and were allocated 
according to order of participant enrolment in the study. 
Participants 
Inclusion criteria: Male and female participants aged 18 to 65 years were eligible to participate if 
they met the DSM-IV criteria for current major depressive disorder and had an Inventory of 
Depressive Symptomatology self-rated version (IDS-SR30) score  14. The diagnosis of major 
depression was made by the first author, an experienced clinical psychologist, using The Mini 
International Neuropsychiatric Interview 6.0 (MINI 6.0) (Sheehan et al., 1998). Pharmaceutical 
antidepressants, the use of the contraceptive pill and no more than once a week use of analgesics 
were permissible. If participants were on pharmaceutical antidepressants, the drug dosage or type 
must have been stable for the past 8 weeks and throughout the duration of the study. Only non-
smokers were included in the study and volunteers were not currently taking turmeric/ curcumin 
supplements. If volunteers were receiving psychological therapy, the treatment must have 
commenced at least 8 weeks prior to participating in the study. 
Exclusion criteria: participants with a psychotic disorder, bipolar disorder, comorbid obsessive-
compulsive disorder, posttraumatic stress disorder, eating disorder, or any substance abuse or 
dependence disorder were excluded, as were participants assessed as having high risk of suicide. 
Volunteers were also excluded if they suffered from medical illnesses including diabetes, 
autoimmune diseases, cardiovascular disease, hypertension, neurodegenerative disorders (e.g., 
Alzheimer’s disease, Parkinson’s disease, stroke, and multiple sclerosis), chronic fatigue syndrome, 
fibromyalgia and asthma; were pregnant or intended to fall pregnant; currently breastfeeding; had 
suffered from an infection or illness over the past month; were currently taking any antiplatelet or 
anticoagulant medications; or had been diagnosed with any coagulation disorder. 
Interventions 
Placebo (cellulose) and curcumin capsules were supplied by Arjuna Natural Extracts Ltd. 
(Kochi, India), and were identical in appearance. Curcumin was provided in a 500 mg capsule 
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(BCM-95®) containing total curcuminoids 88% (curcumin, bisdemethoxycurcumin, 
demethoxycurcumin) and volatile oils 7% from rhizomes of Curcuma longa Linn. Participants were 
directed to take one capsule, twice daily with or without food for 8 weeks. Curcumin was used at a 
dose of 1000 mg/day. Medication compliance was measured by volunteer-reported pill count at 
weeks 4 and 8. 
Outcomes 
Self-report questionnaires 
Inventory of Depressive Symptomatology self-rated version (IDS-SR30): The IDS-SR30 was used 
as the primary outcome measure. It contains 30 items measuring depressive symptoms based on the 
DSM-IV criteria for major depressive episode (Rush et al., 1986, Rush et al., 1996).  Respondents 
are asked to rate the severity and frequency of specific symptoms present over the past 7 days. The 
IDS-SR30 has acceptable psychometric properties in depressed outpatients (Rush et al., 2000, Rush 
et al., 1996, Trivedi et al., 2004) and correlates highly with common depression inventories such as 
the HRSD17, BDI, and MADRS (Corruble et al., 1999, Rush et al., 2000, Rush et al., 1996). 
In a factor analytical study on the IDS-SR30, two dimensions were identified: a ‘mood/cognition’ 
factor representing affective and cognitive symptoms (IDSm), and an ‘anxiety/arousal’ factor 
indicating arousal and somatic complaints (IDSa) (Wardenaar et al., 2010). In addition, items in the 
IDS-SR30 associated with ‘atypical’ and ‘melancholic’ depression have been used for the clinical 
subtyping of these two subtypes of depression (Gili et al., 2012). This item analysis was used to 
categorise volunteers into atypical or melancholic depression.  
The Spielberger State-Trait Anxiety Inventory (STAI): The STAI is a self-report tool for 
assessing anxiety consisting of two subscales (state and trait anxiety) each containing 20 items 
(Spielberger, 1983). The STAI is among the most widely researched and commonly used measures 
of general anxiety and has good reliability and validity (Metzger, 1976, Okun et al., 1996). The 
STAI was considered an appropriate measure given its strong correlation with measures of 
depression (Kennedy et al., 2001). 
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Statistical analysis 
Treatment condition on mood measures 
Two successive analyses were conducted. The first compared curcumin versus placebo groups. 
Second, as an exploratory analysis, volunteers with atypical depression were compared across 
treatment groups (curcumin versus placebo). Analysis of volunteers with melancholic depression 
could not be completed due to limited numbers (n = 3). 
Independent samples t-tests were used to compare demographic variables across the treatment 
groups for continuous variables, and Pearson Chi-squared tests (or Fisher exact test for low cell 
counts) were used to compare categorical data. Individual mood measures (IDS-SR30, STAI, and 
relevant sub-scores) were assessed for differences between baseline, mid-point (week 4) and end-
point (week 8) by a mixed repeated-measures analysis of variance (ANOVA).  
Analyses for time (baseline, midpoint and post-treatment) within each treatment condition, and 
treatment (curcumin and placebo) x time (baseline, midpoint and post-treatment) effects were 
conducted. Planned contrasts were also conducted to compare mood changes at differing time 
points (i.e., baseline to week 4; week 4 to week 8). There were no significant outliers in data as 
assessed by the visual inspection of Q-Q plots, although questionnaire data was not normalised. The 
repeated measures ANOVA was considered appropriate for statistical analyses as it is relatively 
robust to violations of normality when group sample sizes are equivalent (Tabachnick and Fidell, 
2007).  Data from all participants were included in analyses (intention to treat, with multiple 
imputation for missing values). 
For all the tests, statistical significance was set at P< 0.05 (two-tailed). All data were analysed 
using SPSS (version 21; IBM, Armonk, NY). 
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RESULTS 
Study Population 
<< Insert figure 1 near here>> 
Baseline questionnaire and demographic information 
Seventy-seven people were screened for participation in the study and 56 met inclusion/ 
exclusion criteria and were enrolled to participate. Twenty-eight people were randomised into the 
placebo group and 28 into the treatment (curcumin) group. Fifty-two participants completed up to 
week 8. There were 4 drop-outs, one from the placebo group and three from the curcumin group, 
with no significant difference between the dropout rate in each group. Reasons for withdrawal 
included an unexpected visit overseas for family purposes (1 in the curcumin group), flare up of 
digestive complaints (1 in the curcumin group), and inconsistent intake of allocated capsules (1 
each in the curcumin and placebo group). As shown in Tables 1 and 2, there were no significant 
differences between the two groups for any baseline mood questionnaire scores or demographic 
variables, except for distribution of medical illnesses, with greater reported medical illnesses in the 
placebo (n=15) versus curcumin (n=5) group (2 (1) = 7.78, p- = .011). Medical illness was 
therefore included as a covariate in the repeated measures ANOVA analyses. 
<< Insert table 1 and table 2 near here>> 
Exploratory analyses were conducted on 18 participants identified as suffering from atypical 
depression (placebo, n =8; curcumin, n=10). There were no significant differences between the two 
treatment groups for any baseline mood questionnaires. Demographic characteristics were also 
similar across treatment groups, except for differences in mean age (placebo, x  = 50.75; curcumin, 
x  = 40.80). The difference, 9.95, 95% CI [0.81, 19.09] was significant (t(16) = 2.31, p = .035). Age 
was therefore included as a covariate in repeated measures ANOVA analyses on the atypical 
depression sample.  
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Outcome Measures 
Treatment effects on mood measures 
IDS–Depressionmeasures
Changes in IDS scores across both treatment groups and repeated measures ANOVA 
significance values are listed in Table 3. There was a significant reduction in all IDS scores across 
both groups for time although there were no significant group x time interactions for any IDS 
measure across the full 8 weeks of treatment. However, contrasts revealed a significant group x 
time interaction from week 4 to week 8 for IDSm (F1,53 = 6.51, p = .014) and IDS total (F1,53 = 4.22, 
p = .045).  
Further ANOVA analyses revealed that from baseline to week 4 there were significant changes 
in all IDS scores, in both the curcumin and placebo group. However, there were no significant 
changes in any IDS scores from week 4 to week 8 in the placebo group. In the curcumin group, 
there were significant changes in IDS total (F1,27 = 5.50, p = .026), and IDSm (F1,27 = 6.07, p = 
.020) over this time. This indicates that in the placebo group, all improvements in IDS depressive 
scores occurred in the first 4 weeks of treatment, while improvements continued in the curcumin 
condition. 
<< Insert table 3 near here>> 
STAI–Anxietymeasures
Changes in STAI scores across both treatment groups and repeated measures ANOVA 
significance values are listed in Table 3. There were significant reductions in STAIs and STAIt 
scores across both groups for time (p<0.001; for all scores across time). There were no significant 
group x time interactions for either STAIs or STAIt across the full 8 weeks of treatment.  
Further ANOVA analyses revealed that from baseline to week 4 there were significant changes 
in both STAIs and STAIt scores, in both the curcumin and placebo group. However, from week 4 to 
week 8, in the placebo group, there were no significant changes in either score. In the curcumin 
group, there was a significant change in STAIt (F1,27 = 4.36, p = .046), and non-significant trend for 
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STAIs (F1,27 = 3.64, p = .067) over this time. This indicates that in the placebo group, improvements 
in STAI anxiety scores occurred in the first 4 weeks of treatment, while improvements continued in 
the curcumin condition. 
AtypicalDepressionSubgroup
IDS–Depressionmeasures
There was a significant reduction in most IDS scores across both groups for time. In the placebo 
group, there were significant time effects for IDS total (p<0.05), IDSm (p<0.05), but not IDSa 
(p>0.05). In the curcumin group, there were significant time effects for IDS total (p<0.01), IDSm 
(p<0.001), and IDSa (p<0.01). There were no significant group x time interactions in any IDS 
measure across the full 8 weeks of treatment (IDSm, F2,32 = 2.40, p = .110; IDSa F2,32 = 0.62, p = 
.670) although there was a non-significant trend for IDS total (F2,32 = 2.73, p = .088). Contrasts 
revealed a significant group x time interaction from week 4 to week 8 for IDS total (F1,16 = 7.78, p = 
.013) and IDSm (F1,16 = 10.61, p = .006). 
In Figure 2, changes in IDS scores are detailed for each treatment condition. Further ANOVA 
analyses revealed that from baseline to week 4 there were significant changes in IDS total (F1,7 = 
6.13, p = .043) in the placebo group. In the curcumin group there were significant changes in IDS 
total (F1,9 = 8.74, p = .016), IDSm (F1,9 = 10.30, p = .011) and IDSa (F1,9 = 9.11, p = .015) over this 
time period. From week 4 to week 8, there were no further significant changes in any IDS score in 
the placebo group. However, in the curcumin group there were significant changes in IDS total (F1,9 
= 8.62, p = .017), IDSm (F1,9 = 9.86, p = .012), and IDSa (F1,9 = 6.42, p = .032) scores over this 
time. This indicates that in the placebo group, all improvements in IDS depressive scores occurred 
in the first 4 weeks of treatment, while improvements continued in the curcumin condition. 
<< Insert figure 2 near here>> 
STAI–Anxietymeasures
There were significant reductions in STAIs and STAIt scores across both groups for time 
(p<0.001; for all scores across time). There was no significant group x time interactions for either 
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STAIs across the full 8 weeks of treatment. However, contrasts revealed a significant group x time 
interaction from week 4 to week 8 for STAIt (F1,15 = 6.00, p = .027). In Figure 2, changes in STAI 
scores are detailed for each treatment condition. Further ANOVA analyses revealed that from 
baseline to week 4 there were significant changes in STAIt scores, in the curcumin group only (F1,9 
= 11.62, p = .008). Continued significant changes in STAIt occurred from weeks 4 to 8 in the 
curcumin group only (F1,9 = 7.24, p = .025).  
Adverse events 
Details of adverse events reported by participants are included in Table 4. All reported adverse 
events were of minor severity and only one participant in the curcumin intervention withdrew from 
the study as a result of reported side effects. This participant experienced an exacerbation of pre-
existing digestive complaints (stomach bloating and pain). There were no significant differences 
between reported adverse events between placebo and curcumin groups. 
<< Insert table 4 near here>> 
DISCUSSION 
The results of this study provide partial support for the antidepressant and anxiolytic effects of 
curcumin in people suffering from major depressive disorder. While curcumin and placebo were 
equally effective in reducing depressive and anxiety symptoms in the first four weeks of treatment, 
curcumin was significantly more effective than placebo in lowering self-reported depressive and 
anxiety symptoms from weeks 4 to 8. When examining the effects of curcumin in people with 
atypical depression, curcumin had even greater antidepressant and anti-anxiety efficacy compared 
to placebo. Again, equivalent improvements in mood occurred from baseline to week 4 in both 
placebo and curcumin-treated individuals. However, from weeks 4 to 8, curcumin was significantly 
more effective in lowering total depressive symptoms (total IDS score), mood/cognitive depressive 
symptoms (IDSm), arousal-related symptoms (IDSa) and trait anxiety (STAIt). 
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While greater antidepressant effects of curcumin compared to placebo were observed from 
weeks 4 to 8, when evaluating the whole treatment period (i.e., baseline to week 8), curcumin was 
not found to be significantly more effective than placebo in reducing depressive and anxiety 
symptoms. Several explanations could account for this overall non-significant treatment effect: (1) 
it may be that curcumin lacks a true antidepressant effect in people with major depressive disorders, 
at least at the dose prescribed (i.e., 500mg twice daily). However, this argument is countered by 
significant and near significant changes in several mood measures in the second half of treatment; 
(2) it is a reflection of the placebo response, typical in placebo-controlled trials. From a statistical 
point of view, when performing the analyses on the whole treatment period, the positive placebo 
response in the first month of treatment masked the positive gains from curcumin over the second 
study period (weeks 4 to 8).  Placebo responses in depression trials are common and it has been 
suggested that true drug responses are characterised by a 2-week delay, with continued 
improvement thereafter, whereas placebo effects are characterised by abrupt, transient 
improvements (Rothschild and Quitkin, 1992).  Although assessments were not completed until 
week 4, this study confirms a similar pattern of change – that is, in placebo-treated individuals, a 
response in the first month, followed by no change, or even worsening of symptoms thereafter. In 
contrast, curcumin-treated individuals continued to experience improvements over the course of the 
study; (3) the antidepressant effects of curcumin may not begin until after 4 weeks of intake, 
reflecting a slow acting, possibly longer term treatment for depression. It is feasible that specific 
mechanistic changes need to be set in motion and maintained for a period of time before mood 
changes prevail. The high portion of recurrent depressed sufferers enrolled in the study (approx. 70 
percent) may also contribute to curcumin’s slow action in this trial. These possibilities require 
exploration through follow-up studies with larger sample sizes, and extended treatment periods. 
The antidepressant effects of curcumin in people with major depressive disorder have now been 
investigated in two additional randomised clinical trials. As an add-on to newly commenced 
antidepressant medication (escitalopram or venlafaxine XR), curcumin, at a dose of 500 mg/day, 
13 
 
did not enhance treatment efficacy compared to a placebo (Bergman et al., 2013). In this double-
blind, placebo controlled, 5-week trial, there were significant improvements in depressive 
symptoms over time in both treatment groups. In the second study, Sanmukhani et al. (2014) 
compared the antidepressant effects of curcumin alone (500 mg twice daily), fluoxetine alone (20 
mg/day) or curcumin plus fluoxetine (500 mg twice daily and 20 mg/day, respectively) in people 
suffering from major depressive disorder. In this randomised, single-blinded (researcher masked), 
6-week trial, all three treatment conditions were associated with significant improvements in 
depressive symptoms. Group comparisons revealed comparable treatment efficacy across the three 
conditions. Weaknesses associated with this study include the lack of placebo control, and non-
masking of participants from the treatment conditions. 
The current study therefore adds to the aforementioned ones as the length of treatment was 
extended to 8 weeks, double-blind placebo controlled conditions were included, and curcumin was 
used a standalone treatment or was used in patients undergoing pre-existing, stabilised 
antidepressant or psychological therapies. Exploratory analyses on people with atypical depression 
were also conducted, and several questionnaires were used to assess depressive, anxiety and general 
health changes. Further support for the antidepressant effects of curcumin is provided by consistent 
findings of protective behavioural effects in animal models of depression and chronic mild stress 
(Jiang et al., 2013, Sanmukhani et al., 2011, Zhang et al., 2014). 
An important finding from this study is the enhanced antidepressant and anxiolytic efficacy of 
curcumin in people with atypical depression. According to DSM-IV criteria, atypical depression is 
characterised by mood reactivity to actual or potential positive events, and two or more of the 
following features; significant weight gain or increased appetite, hypersomnia, leaden paralysis, and 
a long-standing pattern of interpersonal rejection sensitivity (American Psychiatric Association, 
2000). Compared to healthy individuals, and people with melancholic or non-atypical depression, 
atypical depression is often associated with higher levels of inflammatory markers such as C-
reactive protein (CRP) (Hickman et al., 2013, Lamers et al., 2013), IL-6 and tumour necrosis factor-
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 (TNF-) (Lamers et al., 2013). Due to the anti-inflammatory effects of curcumin, it is this 
immuno-inflammatory dysregulation that may account for the increased efficacy of curcumin in 
people with atypical depression. In a recent meta-analysis on clinical trials it was concluded that 
curcumin lowers CRP levels (Sahebkar, 2014). It can also lower IL-6 (Belcaro et al., 2010, Zhou et 
al., 2011) and TNF- levels (Aggarwal et al., 2013).  
Limitations and Directions for Future Research 
The relatively small samples size used in this study limits the reliability and statistical power 
associated with the findings. For evaluation of curcumin’s antidepressant effects, data from 
approximately 50 participants was obtained. Sample sizes were even lower when evaluating the 
effects of curcumin on people with atypical depression. The results from this study therefore require 
replication with larger sample sizes. 
In this study, a high proportion (approx. 70%) of participants reported a history of multiple 
depressive episodes, thereby reflecting a sample with high chronicity of depression and likely 
treatment resistance. Comparative evaluations of the efficacy of curcumin with single- and 
recurrent-episode depressives would be useful, along with an examination of the influence of 
differing treatment periods and curcumin dosages.  
Investigations into the antidepressant effects of curcumin would also be strengthened by studies 
controlling for important covariates such as medication use, psychological therapies, medical 
illnesses and BMI. While this 8-week study now represents the longest investigation into effects of 
curcumin on depression, future investigations with longer follow up periods are certainly warranted. 
Because the effects of curcumin were not recognised until after week 4, longer treatment duration 
will be necessary to determine if mood improvements maintain or increase over time.  
Self-report instruments were used to monitor changes in mood. While this provides a valid index 
of clinical progress, the implementation of additional measures, such as reliable and valid clinician-
rated instruments, will provide a more robust evaluation of the clinical effectiveness of curcumin. 
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Other areas of interest include investigations into the optimal curcumin dose for best 
antidepressant effects and the frequency of intake. In two studies a dose of 500 mg twice daily has 
been used, and in the other 500 mg once daily was used. Because of problems with bioavailability 
of curcumin, doses greater than these may be necessary to achieve optimal treatment efficacy. 
Increasing intake to 3 times a day may also be necessary to combat problems associated with the 
short half-life of curcumin (Anand et al., 2007). 
 
In conclusion, the present findings provide partial support for the antidepressant effects of 
curcumin in people with major depressive disorder, and particularly atypical depression. However, 
replication with larger clinical trials, using variable doses, and conducted over an extended 
treatment period is required. 
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Table 1. Demographic characteristics of curcumin and placebo 
participants. 
 
Placebo Curcumin p-value n=28 n=28 
Age, years mean (SD) 48.54 (11.73) 44.04 (11.94) 0.16† 
BMI (kg/m2)mean (SD) 27.06 (4.76) 26.12 (5.48) 0.51† 
Sex n 
Female 20 20 1.00# Male 8 8 
Marital Status n 
Single 7 11 
.551# 
Married 12 11 
De facto* 5 4 
Divorced 2 2
Widowed 2 0 
Educational Status n 
Secondary 6 9 
.658# Tertiary 17 15 
Post-graduate 5 4 
General Health n 
Great 9 7 
.194# Average 19 18 
Poor 0 3 
Medical Illness n 
Yes 15 5 .011# No 13 23 
Antidepressant Medication n 
Yes 9 10 1.00# No 19 18 
Antidepressant class n 
SSRI 7 6 .628# SNRI 2 4
Depression episodes n 
Single episode 11 7 .391# Recurrent episodes 17 21 
Exercise Frequency n 
Never/Rarely 6 4
.421# 1-2 times week 9 10 3-5 times week 11 14 
6+ times week 2 0 
Injuries causing regular pain  n 
Yes 14 10 .418# No 14 18 
*Domestic partner outside marriage 
†Independent samples T-test; #Chi-square Test 
SSRI= selective serotonin reuptake inhibitor; SNRI= selective 
serotonin-norepinephrine reuptake inhibitor 
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Table 2. Baseline questionnaire scores between 
curcumin and placebo participants. 
 
Placebo n=28 Curcumin n=28 p-value†mean (SD) mean (SD) 
STAI state 50.25 (13.02) 52.00 (13.17) 0.62 
STAI trait 55.89 (13.24) 56.29 (8.30) 0.90 
IDS 33.14 (9.39) 33.04 (9.39) 0.97 
IDS mood 14.64 (5.67) 13.93 (5.37) 0.63 
IDS arousal 6.68 (2.79) 6.82 (2.40) 0.84 
†Independent samples T-test 
Data are shown as mean (SD)?
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Table 3. Changes in questionnaire scores over time.
Treatment Baseline Week 4 Week 8 
Treatment x Time effect (p-value) 
  Baseline-week 4 
week 4- 
week 8 
Baseline - 
week 8 
STAI- State, 
mean (SD) 
Placebo 
(n=28) 
50.
25 
(13.
02) 
43.
14b 
(13.
30) 
43.2
1f 
(12.
94) .687 .255 .595 Curcumin 
(n=28) 
52.
00 
(13.
17)
45.
89b
(12.
65)
42.2
9d,g
(12.
21)
STAI- Trait, 
mean (SD) 
Placebo 
(n=28) 
55.
89 
(13.
25) 
49.
82b 
(12.
79) 
50.2
1f 
(9.4
1) .516 .097 .358 Curcumin 
(n=28) 
56.
29 
(8.3
0) 
50.
75c
(9.4
6)
47.9
6d,f
(11.
32)
IDS - Total, 
mean (SD) 
Placebo 
(n=28) 
33.
14 
(11.
88) 
25.
82c 
(14.
55) 
25.8
9f 
(13.
43) .313 .045* .189 Curcumin 
(n=28) 
33.
04 
(9.3
9) 
26.
61c 
(11.
87) 
22.7
1d,f 
(9.3
6) 
IDS- Mood, 
mean (SD) 
Placebo 
(n=28) 
14.
64 
(5.6
7) 
10.
50c 
(6.8
8) 
11.0
0f 
(6.6
0) .496 .014* .192 Curcumin 
(n=28) 
13.
93 
(5.3
7) 
11.
00c 
(5.3
4) 
9.25
d,f 
(4.4
2) 
IDS- Arousal, 
mean (SD) 
Placebo 
(n=28) 
6.6
8 
(2.7
9) 
5.6
4c 
(3.3
7) 
5.25
e 
(3.1
2) .282 .312 .489 Curcumin 
(n=28) 
6.8
2 
(2.4
0) 
5.5
7c 
(3.1
8) 
4.71
f 
(2.8
1) 
Medical illness included as covariate 
ap < . 05; bp < . 01; cp < . 001 - within group significant time effects from baseline to week 4 
dp < . 05 - within group significant time effects from week 4 to week 8 
ep < . 01; fp < . 001 - within group significant time effects from baseline to week 8 
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Table 4: List and frequency of adverse events reported by participants. 
Curcumin Placebo 
Frequency Reported complaints Frequency Reported complaints 
16 No adverse events 14 No adverse events 
7 Digestive: stomach bloating, nausea, mild diarrhoea 6 
Digestive: appetite change, bloating, mild 
diarrhoea
0 Respiratory: none 1 Respiratory: breathing problems 
3 Dermatological: dry skin, flaking skin 2 Dermatological: dry skin, flaking skin, itchy skin 
2 Neurological: headaches, dizziness 2 Neurological: memory slower, tingling in hands 
2 Pain: joint pain, back pain 4 Pain: joint pain, back pain, neck pain 
2 Cardiovascular: racing heart, chest pain 0 Cardiovascular: none 
3 Visual: sore eyes, dry eyes, blurry vision 0 Visual: none 
1 Auditory: ringing in ears 2 Auditory: ringing in ears 
2 Oral: dry mouth, sore gums 2 Oral: dry mouth, mouth ulcers 
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Figure 2. Atypical depression - Change in mood scores over time (± 1 Std. error) across curcumin and 
placebo groups. * (p<.05); **(p<.01) indicates significant group x time interaction for specified period 
* ** 
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